Drug Profile
Research programme: dermal-derived cell therapies - Fibrocell Science/University of California at Los Angeles
Alternative Names: Autologous dermal fibroblast cell therapies - Fibrocell Science/UCLA; Autologous dermal mesenchymal adult stem cell therapies - Fibrocell Science/UCLA; Autologous dermal SERA cell therapies - Fibrocell Science/UCLA; Autologous dermal SSEA3-expressing regeneration-associated cell therapies - Fibrocell Science/UCLALatest Information Update: 19 Dec 2019
Price :
$50
*
At a glance
- Originator Fibrocell Science; University of California at Los Angeles
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; Unspecified
Most Recent Events
- 16 Dec 2019 Fibrocell Science has been acquired by Castle Creek Pharmaceuticals
- 28 Jul 2018 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 28 Jul 2018 No recent reports of development identified for research development in Undefined in USA (Injection)